{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:54:20Z","timestamp":1795190060017,"version":"4.10.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04161-9","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:30:40Z","timestamp":1754487040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4116-2778","authenticated-orcid":false,"given":"Paula","family":"Dibo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1396-3910","authenticated-orcid":false,"given":"Naga Sai Rasagna","family":"Mareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4719-2195","authenticated-orcid":false,"given":"Giovana Schlichta Adriano","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5092-517X","authenticated-orcid":false,"given":"Mohamad","family":"Ershed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4184-9644","authenticated-orcid":false,"given":"Ogechukwu Samuel","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Razaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-463X","authenticated-orcid":false,"given":"Vineeta","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","volume":"34","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803\u201305.","journal-title":"Nephrol Dial Transplant"},{"key":"4161_CR2","doi-asserted-by":"crossref","unstructured":"Strohmaier S, Wallisch C, Kammer M, Geroldinger A, Heinze G, Oberbauer R, et al. Survival benefit of first single-organ deceased donor kidney transplantation compared with long-term dialysis across ages in transplant-eligible patients with kidney failure. JAMA Network Open. 2022;5:e2234971.","DOI":"10.1001\/jamanetworkopen.2022.34971"},{"key":"4161_CR3","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1002\/cphy.c190043","volume-title":"Comprehensive Physiology","author":"JG Johnston","year":"2023","unstructured":"Johnston JG, Welch AK, Cain BD, Sayeski PP, Gumz ML, Wingo CS. Aldosterone: renal action and physiological effects. In: Comprehensive Physiology, Wiley, 2023:4409\u201391."},{"key":"4161_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11886-022-01750-0","volume":"24","author":"JD Ravid","year":"2022","unstructured":"Ravid JD, Laffin LJ. Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure. Curr Cardiol Rep. 2022;24:1251\u201359.","journal-title":"Curr Cardiol Rep"},{"key":"4161_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1432-2277.2011.01242.x","volume":"24","author":"C Ponticelli","year":"2011","unstructured":"Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transplant Int. 2011;24:523\u201333.","journal-title":"Transplant Int"},{"key":"4161_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jama.283.5.633","volume":"283","author":"KC Mange","year":"2000","unstructured":"Mange KC. Arterial hypertension and renal allograft survival. JAMA. 2000;283:633.","journal-title":"JAMA"},{"key":"4161_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12882-018-0885-6","volume":"19","author":"LA Mortensen","year":"2018","unstructured":"Mortensen LA, Thiesson HC, Tougaard B, Egfjord M, Fischer ASL, Bistrup C. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial). BMC Nephrol. 2018;19:105.","journal-title":"BMC Nephrol"},{"key":"4161_CR8","doi-asserted-by":"crossref","unstructured":"Baskin E, Siddiqui MA, G\u00fcllero\u011flu K, \u00d6zdemir BH, Y\u0131lmaz A\u00c7, \u00c7olak MY, et al. Long-term effect of eplerenone treatment in children with chronic allograft nephropathy. Pediatr Transplant. 2023;27.","DOI":"10.1111\/petr.14557"},{"key":"4161_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40620-019-00681-4","volume":"33","author":"AM Abdelhakim","year":"2020","unstructured":"Abdelhakim AM, Abd-elgawad M. Impact of mineralocorticoid receptor antagonist in renal transplant patients: a systematic review and meta-analysis of randomized controlled trials. J Nephrol. 2020;33:529\u201338.","journal-title":"J Nephrol"},{"key":"4161_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nded. Chichester (UK): John Wiley & Sons; 2019.","edition":"2nd"},{"issue":"1","key":"4161_CR11","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(1):b2535.","journal-title":"BMJ"},{"key":"4161_CR12","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;4898.","DOI":"10.1136\/bmj.l4898"},{"key":"4161_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.","journal-title":"BMJ"},{"key":"4161_CR14","unstructured":"GRADE Handbook. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html (24 August 2023)."},{"key":"4161_CR15","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon J, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21:2641\u201352.","journal-title":"Stat Med"},{"key":"4161_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evidence Based Mental Health. 2019;22:153\u201360.","journal-title":"Evidence Based Mental Health"},{"key":"4161_CR17","doi-asserted-by":"publisher","unstructured":"Mortensen LA, Jespersen B, Helligsoe ASL, Tougaard B, Cibulskyte-Ninkovic D, Egfjord M, et al. Effect of spironolactone on kidney function in kidney transplant recipients (the SPIREN trial). Clin J Am Soc Nephrol. 2024; https:\/\/doi.org\/10.2215\/CJN.0000000000000439.","DOI":"10.2215\/CJN.0000000000000439"},{"key":"4161_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000350539","volume":"37","author":"M Ojeda-Cervantes","year":"2013","unstructured":"Ojeda-Cervantes M, Barrera-Chimal J, Alber\u00fa J, P\u00e9rez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. Am J Nephrol. 2013;37:481\u201390.","journal-title":"Am J Nephrol"},{"key":"4161_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2215\/CJN.05300516","volume":"12","author":"M Medeiros","year":"2017","unstructured":"Medeiros M, Vel\u00e1squez-Jones L, Hern\u00e1ndez AM, Ram\u00f3n-Garc\u00eda G, Valverde S, Fuentes Y, et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol. 2017;12:1291\u2013300.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4161_CR20","doi-asserted-by":"crossref","unstructured":"Morales-Buenrostro LE, Ortega-Trejo JA, P\u00e9rez-Villalva R, Marino LA, Gonz\u00e1lez-Bobadilla Y, Ju\u00e1rez H, et al. Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial. Am J Physiol Renal Physiol. 2019;317:F519\u201328.","DOI":"10.1152\/ajprenal.00606.2018"},{"key":"4161_CR21","doi-asserted-by":"publisher","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","volume":"10","author":"H Minakuchi","year":"2020","unstructured":"Minakuchi H, Wakino S, Urai H, Kurokochi A, Hasegawa K, Kanda T, et al. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial. Sci Rep. 2020;10:16626.","journal-title":"Sci Rep"},{"key":"4161_CR22","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116\u201323.","journal-title":"Kidney Int"},{"key":"4161_CR23","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","volume":"37","author":"M-E Alexandrou","year":"2019","unstructured":"Alexandrou M-E, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. J Hypertens. 2019;37:2307\u201324.","journal-title":"J Hypertens"},{"key":"4161_CR24","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/ndt\/gfl227","volume":"21","author":"UB Berg","year":"2006","unstructured":"Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant. 2006;21:2577\u201382.","journal-title":"Nephrol Dial Transplant"},{"key":"4161_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1053\/j.ajkd.2011.12.014","volume":"59","author":"MZ Molnar","year":"2012","unstructured":"Molnar MZ, Streja E, Kovesdy CP, Shah A, Huang E, Bunnapradist S, et al. Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes. Am J Kidney Dis. 2012;59:841\u201348.","journal-title":"Am J Kidney Dis"},{"key":"4161_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ddr.21760","volume":"82","author":"V Patel","year":"2021","unstructured":"Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82:341\u201363.","journal-title":"Drug Dev Res"},{"key":"4161_CR27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","volume":"24","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Ferreira JP, Rossignol P, Neuen BL, Claggett BL, Pfeffer MA, et al. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail. 2022;24:1586\u201390.","journal-title":"Eur J Heart Fail"},{"key":"4161_CR28","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.3390\/ijms22189995","volume":"22","author":"W Baran","year":"2021","unstructured":"Baran W, Krzemi\u0144ska J, Szlagor M, Wronka M, M\u0142ynarska E, Franczyk B, et al. Mineralocorticoid receptor antagonists\u2014use in chronic kidney disease. Int J Mol Sci. 2021;22:9995.","journal-title":"Int J Mol Sci"},{"key":"4161_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199\u2013211.","journal-title":"Am J Kidney Dis"},{"key":"4161_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","volume":"19","author":"S Kato","year":"2015","unstructured":"Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol. 2015;19:1098\u2013106.","journal-title":"Clin Exp Nephrol"},{"key":"4161_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534366","volume":"55","author":"C-Y Yuan","year":"2024","unstructured":"Yuan C-Y, Gao Y-C, Lin Y, Liu L, Shen X-G, Zou W-L, et al. Effects of mineralocorticoid receptor antagonists for chronic kidney disease: a systemic review and meta-analysis. Am J Nephrol. 2024;55:1\u201317.","journal-title":"Am J Nephrol"},{"key":"4161_CR32","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"4161_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ndt\/gfac157","volume":"38","author":"LM Ruilope","year":"2023","unstructured":"Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, et al. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38:372\u201383.","journal-title":"Nephrol Dial Transplant"},{"key":"4161_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","volume":"76","author":"G Bakris","year":"2020","unstructured":"Bakris G, Yang YF, Pitt B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease. Hypertension. 2020;76:144\u201349.","journal-title":"Hypertension"},{"key":"4161_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/jcm7110459","volume":"7","author":"C-T Yang","year":"2018","unstructured":"Yang C-T, Kor C-T, Hsieh Y-P. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J Clin Med. 2018;7:459.","journal-title":"J Clin Med"},{"key":"4161_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"4161_CR37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","volume":"16","author":"NM Berbenetz","year":"2016","unstructured":"Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04161-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T21:29:26Z","timestamp":1757366966000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04161-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04161-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no relationships that could be considered as a conflict of interest. All authors take responsibility for all aspects of reliability and freedom from bias of the data presented and their discussed interpretation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"438"}}